Twist Bioscience Corp. Stock News

The stock price of Twist Bioscience Corp (NASDAQ: TWST) fell by 18.09% in the most recent trading session. This is why.

Twist Bioscience Corp (NASDAQ:TWST ) Q1 2023 Earnings Conference Call February 3, 2023 8:00 AM ET Company Participants Angela Bitting - Chief ESG Officer & SVP, Corporate Affairs Emily Leproust - Co-F

Investors didn't like the synthetic DNA maker's guidance.

Twist Bioscience (TWST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Wall Street analysts make new stock picks on a daily basis. Unfortunately for investors, not all analysts have particularly impressive track records at predicting market movements. Even when it comes

SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silico

Keybanc raised the price target on AMETEK, Inc. (NYSE: AME) from $145 to $165. Keybanc analyst Steve Barger maintained an Overweight rating on the stock. AMETEK shares rose 0.9% to close at $139.32 o

Analysts have provided the following ratings for Twist Bioscience (NASDAQ:TWST) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 2 2 0 0

Societe Generale boosted the price target on ConocoPhillips (NYSE: COP) from $106 to $114. ConocoPhillips shares fell 2% to close at $128.59 on Friday. HC Wainwright & Co. cut LiveOne, Inc. (NASD

Twist Bioscience (TWST) delivered earnings and revenue surprises of 28.91% and 0.56%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Twist Bioscience Corporation (NASDAQ:TWST ) Q4 2022 Earnings Conference Call November 18, 2022 8:00 AM ET Company Participants Angela Bitting - Senior Vice President, Corporate Affairs & Chief ESG Off

Twist Bioscience (TWST) delivered earnings and revenue surprises of 28.91% and 0.56%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Investors were spooked by a short-seller's allegations.

Investors were spooked by a short-seller's allegations.

Twist Bioscience Corp. stock slid 20% Tuesday, after a damning short seller report compared the company to the failed blood-testing startup Theranos, calling it a "cash-burning inferno" and a "'synthe